8-K: Venus Concept Secures Loan Amendments, New Drawdown

Venus Concept Inc. announced a consent agreement for its Main Street Priority Loan, a twenty-first amendment to its Bridge Loan extending maturity, and a new $2 million drawdown for working capital.

Summary

• Venus Concept Inc. (the Company) entered into a Consent Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP (the Lenders) on October 31, 2025.
• The Consent Agreement waives certain minimum liquidity requirements under the Main Street Priority Loan (MSLP Loan Agreement) through November 30, 2025.
• It also permits Venus USA to apply the November 8, 2025 cash interest payment due under the Notes to the respective outstanding principal balance (Paid-in-Kind interest).
• The Company also entered into a Twenty First Bridge Loan Amendment Agreement with the Lenders on October 31, 2025.
• This amendment extends the maturity date of the Bridge Loan from October 31, 2025, to November 30, 2025.
• It also waives certain minimum liquidity requirements under the Bridge Loan Agreement through November 30, 2025.
• On October 28, 2025, the Lenders provided a Thirteenth Delayed Drawdown of $2,000,000 under the Bridge Financing.
• The total aggregate principal amount of the Bridge Financing is now up to $28,237,906.85, bearing interest at 12% per annum.
• The proceeds from the Thirteenth Delayed Drawdown are expected to be used for general working capital purposes.

Sentiment

Score: 3

Explanation: While the company secured immediate liquidity and avoided default on certain covenants, the short-term nature of the extensions (one month), the high interest rate on bridge financing, the continuous need for drawdowns, and the use of PIK interest payments highlight severe ongoing financial distress and a precarious liquidity position. This suggests a company struggling to maintain operations and facing significant challenges in securing stable, long-term financing.

Positives

• Secured an additional $2,000,000 in bridge financing, providing immediate liquidity.
• Obtained waivers for minimum liquidity requirements under both the MSLP Loan Agreement and the Bridge Loan Agreement through November 30, 2025, preventing potential defaults.
• Extended the maturity date of the Bridge Loan to November 30, 2025, providing a short-term reprieve.
• Permission to pay November 2025 interest in-kind (PIK) rather than cash preserves cash liquidity.

Negatives

• The need for continuous waivers of minimum liquidity requirements suggests ongoing financial strain and potential cash flow issues.
• The Bridge Loan maturity date was extended by only one month (from October 31, 2025, to November 30, 2025), indicating a very short-term solution and persistent uncertainty regarding long-term financing.
• The interest rate on the Bridge Financing is high at 12% per annum, increasing debt servicing costs.
• The company is relying heavily on bridge financing, having drawn down 13 times, which points to a lack of sustainable operating cash flow or access to more conventional financing.
• Paying interest in-kind (PIK) increases the principal balance of the loan, leading to higher future repayment obligations.

Risks

• Liquidity Risk: The company required waivers for minimum liquidity requirements, indicating potential challenges in maintaining sufficient cash on hand.
• Refinancing Risk: The Bridge Loan maturity was extended by only one month, suggesting a high risk of needing further extensions or a more permanent refinancing solution very soon.
• Debt Burden Risk: The continuous drawdowns and high interest rate (12%) on the Bridge Financing, coupled with PIK interest, increase the overall debt burden and future repayment obligations.
• Operational Risk: The use of proceeds for "general working capital purposes" suggests that the company is using debt to fund day-to-day operations, which is unsustainable in the long term without improved profitability.
• Default Risk: The need for waivers on loan covenants indicates the company is operating close to or in breach of its debt agreements, increasing the risk of default if further accommodations are not secured.

Future Outlook

The company expects to use the proceeds of the Thirteenth Delayed Drawdown for general working capital purposes. The short-term extension of the Bridge Loan maturity to November 30, 2025, indicates that further financing or restructuring will be required in the very near future.

Industry Context

This filing primarily addresses the company's specific debt and liquidity management, rather than broader industry trends. The need for continuous bridge financing and waivers suggests company-specific financial challenges rather than a reflection of the overall medical aesthetics or device industry.

Stakeholder Impact

• Shareholders: Increased debt burden and high interest rates could dilute equity value or impact future profitability. The continuous need for short-term financing signals significant financial risk.
• Creditors (Madryn Health Partners): Their position is strengthened by the reaffirmation of obligations and the release provision, but they are also extending credit to a company with ongoing liquidity challenges.
• Employees: Continued operations are supported by the new drawdown, but the underlying financial instability could pose long-term job security concerns.

Next Steps

• The company will need to address the Bridge Loan's maturity by November 30, 2025.
• The company will need to ensure compliance with liquidity requirements after November 30, 2025.
• The company will need to manage its general working capital effectively using the new drawdown.

Key Dates

Recommendation

The filing reveals a company in significant financial distress, characterized by a persistent reliance on high-interest bridge financing, repeated short-term extensions of debt maturity, and the need for waivers on critical liquidity covenants. The decision to pay interest in-kind further exacerbates the debt burden. These factors collectively point to severe cash flow issues and an unsustainable capital structure, making the stock a high-risk investment with substantial downside potential. The one-month extension offers only a temporary reprieve, indicating that the company will face similar, if not more acute, challenges very soon.

Keywords

Venus Concept, VERO, SEC Filing, 8-K, Bridge Loan, Loan Amendment, Liquidity Waiver, Debt Financing, Working Capital, Madryn Health Partners, Main Street Priority Loan, PIK Interest